In accordance, in the CN-AML patient cohort univariate analysis revealed R2high/noFLT3-ITD genotype (HR, 0.507; 95%-CI, 0.275 to 0.936; p=0.03), NPM1mut/noFLT3-ITD genotype (HR, 0.515; 95%-CI, 0.273 to 0.97; p=0.004), FLT3-ITD alteration (HR, 1.987; 95%-CI, 1.187 to 3.325; p=0.009), high WBC (HR, 1.007; 95%-CI, 1.002 to 1.013; p=0.006), and age (HR, 1.054; 95%-CI, 1.028 to 1.08, p<0.001), but not gender, CEBPA, NRAS, FLT3-TKD or NPM1 mutations, as significant variables for OS (Table 2). The gene discussed is FLT3; the disease is acute myeloid leukemia.